This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vahl, N. Articles by Christiansen, Jens. S. Search for Related Content PubMed PubMed Citation Articles by Vahl, N. Articles by Christiansen, Jens. S.

Continuation of Growth Hormone (GH) Replacement in GH-Deficient Patients during Transition from Childhood to Adulthood: A Two-Year Placebo-Controlled Study

Medical Department M (Endocrinology and Diabetes) (N.V., J.O.L.J., J.S.C.), Aarhus Kommunehospital, Aarhus DK-8000 C, Denmark; Department of Growth and Reproduction (A.J., N.E.S.), Rigshopitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark; Center for Clinical Pharmacology (J.O.L.J., J.S.C.), Aarhus University Hospital, Aarhus, Denmark; and Institute of Clinical Experimental Research (H.Ø.), Aarhus University Hospital, Aarhus, Denmark

Address correspondence and requests for reprints to: Nina Vahl, M.D., Medical Department M, Aarhus Kommunehospital, Aarhus DK-8000 C, Denmark. E-mail: nvahl{at}dadlnet.dk

Previous studies have demonstrated beneficial effects of GH replacement, in adults with GH deficiency (GHD), on body composition, physical fitness, and quality of life. These studies, however, concern patients with adult-onset GHD or childhood-onset (CO) patients enrolled several years after withdrawal of initial therapy. So far, the effects of continuation of GH-administration in patients with CO-GHD have not been examined. We studied a group of nineteen young adults (13 males + 6 females; 16–26 yr old; mean age, 20.2 ± 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr. All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose. Patients randomized to continued GH treatment exhibited no significant changes in any parameters tested, but intra- and interindividual variations in insulin-like growth factor (IGF)-I levels could suggest compliance problems. Discontinuation of GH for 1 yr resulted in a decrease in serum IGF-I, from 422.0 ± 56.8 to 147.8 ± 33.4 µg/L, in the placebo group (P = 0.003). After discontinuation of GH for 1 yr, an increase in total body fat (TBF, kg), measured by dual-energy x-ray absorptiometry scan, was seen [placebo: 22.7 ± 2.7 to 26.5 ± 2.5 (P = 0.01); GH:16.2 ± 2.1 to 17.2 ± 2.1 (not significant)]. Resumption of GH after placebo was followed by increments in serum IGF-I (µg/L) [from 147.8 ± 33.4 to 452 ± 76 (P = 0.001)] and IGF-binding protein 3, as well as in fasting glucose (mmol/L) [4.9 ± 0.2 vs. 5.3 ± 0.2 (P = 0.03)]. After resumption of GH lean body mass (kg) increased [52.4 ± 4.9 vs. 60.7 ± 5.6 (P = 0.006)]. Likewise, resumption of GH therapy increased thigh muscle volume and thigh muscle/fat ratio, as assessed by computed tomography [muscle volume (cm²/10 mm): 118.2 ± 11.7 vs. 130.0 ± 10.9 (P = 0.002); muscle/fat ratio: 1.33 ± 0.24 vs. 1.69 ± 0.36 (P = 0.02)].

In conclusion, discontinuation of GH treatment in GHD patients, during the transition from childhood to adulthood, induces significant and potentially unfavorable changes in IGF-I and body composition, both of which are reversed after resumption of GH treatment. By contrast, continuation of GH therapy results in unaltered IGF-I and body composition. We recommend continuation of GH therapy in these patients, to be undertaken in collaboration between pediatricians and adult endocrinologists.

This article has been cited by other articles:

				A. Fernandez, M. Brada, L. Zabuliene, N. Karavitaki, and J. A H Wass Radiation-induced hypopituitarism Endocr. Relat. Cancer, September 1, 2009; 16(3): 733 - 772. [Abstract] [Full Text] [PDF]

				O. Klefter and U. Feldt-Rasmussen Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with GH-treated GH deficiency? A systematic literature analysis Eur. J. Endocrinol., August 1, 2009; 161(2): 213 - 221. [Abstract] [Full Text] [PDF]

				G S Conway, M Szarras-Czapnik, K Racz, A Keller, P Chanson, M Tauber, M Zacharin, and on behalf of the 1369 GHD to GHDA Transition Study Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency Eur. J. Endocrinol., June 1, 2009; 160(6): 899 - 907. [Abstract] [Full Text] [PDF]

				N. di Iorgi, A. Secco, F. Napoli, C. Tinelli, A. Calcagno, N. Fratangeli, L. Ambrosini, A. Rossi, R. Lorini, and M. Maghnie Deterioration of Growth Hormone (GH) Response and Anterior Pituitary Function in Young Adults with Childhood-Onset GH Deficiency and Ectopic Posterior Pituitary: A Two-Year Prospective Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3875 - 3884. [Abstract] [Full Text] [PDF]

				S. Radovick and S. DiVall Approach to the Growth Hormone-Deficient Child during Transition to Adulthood J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1195 - 1200. [Abstract] [Full Text] [PDF]

				A Ciresi, M C Amato, A Criscimanna, A Mattina, C Vetro, A Galluzzo, G D'Acquisto, and C Giordano Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency Eur. J. Endocrinol., March 1, 2007; 156(3): 353 - 360. [Abstract] [Full Text] [PDF]

				J. Svensson, G. Johannsson, A. Iranmanesh, K. Albertsson-Wikland, J. D Veldhuis, and B.-A. Bengtsson GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. Eur. J. Endocrinol., July 1, 2006; 155(1): 91 - 99. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				N. Mauras, O. H. Pescovitz, V. Allada, M. Messig, M. P. Wajnrajch, B. Lippe, and on behalf of the Transition Study Group Limited Efficacy of Growth Hormone (GH) during Transition of GH-Deficient Patients from Adolescence to Adulthood: A Phase III Multicenter, Double-Blind, Randomized Two-Year Trial J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3946 - 3955. [Abstract] [Full Text] [PDF]

				A. Mukherjee, S. Tolhurst-Cleaver, W. D. J. Ryder, L. Smethurst, and S. M. Shalet The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1542 - 1549. [Abstract] [Full Text] [PDF]

				P E Clayton, R C Cuneo, A Juul, J P Monson, S M Shalet, and M Tauber Consensus statement on the management of the GH-treated adolescent in the transition to adult care Eur. J. Endocrinol., February 1, 2005; 152(2): 165 - 170. [Abstract] [Full Text] [PDF]

				H K Gleeson and S M Shalet The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours Endocr. Relat. Cancer, December 1, 2004; 11(4): 589 - 602. [Abstract] [Full Text] [PDF]

				A. F. Attanasio, E. Shavrikova, W. F. Blum, M. Cromer, C. J. Child, M. Paskova, J. Lebl, J. J. Chipman, the Hypopituitary Developmental Outcome Study Grou, and S. M. Shalet Continued Growth Hormone (GH) Treatment after Final Height Is Necessary to Complete Somatic Development in Childhood-Onset GH-Deficient Patients J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4857 - 4862. [Abstract] [Full Text] [PDF]

				P. V. Carroll, W. M. Drake, K. T. Maher, K. Metcalfe, N. J. Shaw, D. B. Dunger, T. D. Cheetham, C. Camacho-Hubner, M. O. Savage, and J. P. Monson Comparison of Continuation or Cessation of Growth Hormone (GH) Therapy on Body Composition and Metabolic Status in Adolescents with Severe GH Deficiency at Completion of Linear Growth J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3890 - 3895. [Abstract] [Full Text] [PDF]

				A. R. Hoffman, J. E. Kuntze, J. Baptista, H. B. A. Baum, G. P. Baumann, B. M. K. Biller, R. V. Clark, D. Cook, S. E. Inzucchi, D. Kleinberg, et al. Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2048 - 2056. [Abstract] [Full Text] [PDF]

				H. K. Gleeson, H. R. Gattamaneni, L. Smethurst, B. M. Brennan, and S. M. Shalet Reassessment of Growth Hormone Status Is Required at Final Height in Children Treated with Growth Hormone Replacement after Radiation Therapy J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 662 - 666. [Abstract] [Full Text] [PDF]

				M. Tauber, B. Jouret, A. Cartault, N. Lounis, M. Gayrard, C. Marcouyeux, C. Pienkowski, I. Oliver, P. Moulin, P. Otal, et al. Adolescents with Partial Growth Hormone (GH) Deficiency Develop Alterations of Body Composition after GH Discontinuation and Require Follow-Up J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5101 - 5106. [Abstract] [Full Text] [PDF]

				L. E. Underwood, K. M. Attie, and J. Baptista Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5273 - 5280. [Abstract] [Full Text] [PDF]

				S. M. Shalet, E. Shavrikova, M. Cromer, C. J. Child, E. Keller, J. Zapletalova, T. Moshang, W. F. Blum, J. J. Chipman, C. A. Quigley, et al. Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4124 - 4129. [Abstract] [Full Text] [PDF]

				Y. van Pareren, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Effect of Discontinuation of Growth Hormone Treatment on Risk Factors for Cardiovascular Disease in Adolescents Born Small for Gestational Age J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 347 - 353. [Abstract] [Full Text] [PDF]

				A. F. Attanasio, S. Howell, P. C. Bates, P. Frewer, J. Chipman, W. F. Blum, and S. M. Shalet Body Composition, IGF-I and IGFBP-3 Concentrations as Outcome Measures in Severely GH-Deficient (GHD) Patients after Childhood GH Treatment: A Comparison with Adult Onset GHD Patients J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3368 - 3372. [Abstract] [Full Text] [PDF]

				D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF]

				L. Hulthen, B.-A. Bengtsson, K. S. Sunnerhagen, L. Hallberg, G. Grimby, and G. Johannsson GH Is Needed for the Maturation of Muscle Mass and Strength in Adolescents J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4765 - 4770. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				R. Roubenoff and V. A. Hughes Sarcopenia: Current Concepts J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2000; 55(12): 716M - 724. [Abstract] [Full Text]